Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables: 2010-2025

Historic Payables for Aytu Biopharma (AYTU) over the last 16 years, with Jun 2025 value amounting to $10.6 million.

  • Aytu Biopharma's Payables fell 30.60% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year decrease of 6.20%. This contributed to the annual value of $10.6 million for FY2025, which is 16.59% down from last year.
  • Per Aytu Biopharma's latest filing, its Payables stood at $10.6 million for FY2025, which was down 16.59% from $12.7 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Payables ranged from a high of $19.3 million in FY2021 and a low of $10.6 million during FY2025.
  • Its 3-year average for Payables is $12.8 million, with a median of $12.7 million in 2024.
  • Per our database at Business Quant, Aytu Biopharma's Payables skyrocketed by 52.55% in 2021 and then dropped by 23.14% in 2022.
  • Aytu Biopharma's Payables (Yearly) stood at $19.3 million in 2021, then fell by 23.14% to $14.8 million in 2022, then rose by 1.63% to $15.0 million in 2023, then decreased by 15.50% to $12.7 million in 2024, then fell by 16.59% to $10.6 million in 2025.